Evolus Q3 revenue +27% to $33.9M; reiterates FY2022 guidance at top end

Evolus, Inc.

2022-Q3 EPS reported -$1.09 revenue$104,970,000

Revenue $33.9M (+27% YoY); deferred $3.5M incremental due to 'Switch Your Tox' campaign, understating growth.
FY2022 revenue guidance top end $143-150M; non-GAAP opex guidance lowered to lower half of $135-140M.
Cash $65.6M; expects to fund through breakeven; operating cash use $17.1M, $3.8M less than Q2.
Added 650 new accounts (total >8,800); Evolus Rewards ~450,000 members with record 100,000 redemptions.
Launched Great Britain ops for Nuceiva; Phase II extra-strength Jeuveau enrollment completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evolus, Inc. reported full-year 2022 results: revenue $143 to $150 million. Guidance reaffirmed.

Period: full-year 2022
Revenue: $143 to $150 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

the company continues to project full-year 2022 sales at the top end of its guidance range of $143 to $150 million, which includes a minimal contribution from international markets.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evolus, Inc. reported third quarter ended September 30, 2022 results: revenue $33.9 million.

Period: third quarter ended September 30, 2022
Revenue: $33.9 million
Result: reported results

Exact text from the filing

Total net revenues for the third quarter of 2022 increased 27% to $33.9 million from $26.7 million in the third quarter of 2021 driven almost entirely by higher volumes of Jeuveau

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

Evolus, Inc. filing history →

Source: SEC EDGAR

accession 0001570562-22-000141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.